|
Hemogenyx Pharmaceuticals PLC on Tuesday said it is has signed a letter of intent with Cellin Technologies OU, a Tallinn-based cell therapy company. Hemogenyx, a London-headquartered biopharmaceutical company focused on treatments for blood diseases, said it explores the commercialisation for its HG-CT-1 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukaemia, a form of blood cancer. The exploration is via the hospital exemption pathway under Estonia’s Medicinal Products Act, which was amended in April and permits the use of certain advanced therapy medicinal products that have not yet been authorised for commercial marketing to treat an unlimited number of patients. This is subject to sufficient preclinical or phase 1 clinical trial data. Hemogenyx Chief Executive Officer & Co-Founder Vladislav Sandler said: ‘Our first priority is to save the lives of patients with relapsed or refractory AML, for whom treatment options remain scarce. Building on this mission, the partnership with Cellin also creates a path to generate initial revenues from HG-CT-1 under Estonia’s hospital exemption pathway, while providing valuable real-world patient data to complement our Phase I trial and support the future development and commercialization of the therapy.’ Cellin board member Ivari Saar said: ‘We are thrilled to partner with Hemogenyx Pharmaceuticals to bring next-generation CAR-T therapy to Estonia, marking a major milestone for patients with acute myeloid leukemia and other hard-to-treat blood cancers. This collaboration positions Estonia at the forefront of advanced cell therapy in Europe, combining scientific innovation with a commitment to accessible care. Together, we aim to demonstrate how CAR-T can deliver transformative outcomes for patients across the EU.’ Hemogenyx shares rose 1.8% to 1,465.32 pence each on Tuesday afternoon in London. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
